BAT 1006
Alternative Names: BAT-1006Latest Information Update: 26 Sep 2025
At a glance
- Originator Bio-Thera Solutions
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Solid tumours
Most Recent Events
- 30 May 2025 Efficacy and adverse events data from a phase I/II trial in Solid tumours presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
- 28 Mar 2025 No recent reports of development identified for phase-I development in Solid-tumours(In the elderly, Late-stage disease, Metastatic disease, Second-line therapy or greater, In adults) in China (IV, Injection)
- 17 Jun 2024 Bio-Thera Solutions completes phase I trial in Solid tumours (In adults, In the elderly, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV) (NCT05414136)